116 related articles for article (PubMed ID: 4039775)
41. [The control of chemotherapy-induced nausea and vomiting].
Shinkai T; Saijo N; Sawamura N; Funaki U; Takahashi S; Yokoyama S; Fujita J; Futami H; Sasaki Y; Shimizu E
Gan No Rinsho; 1985 Jun; 31(7):779-91. PubMed ID: 3897622
[TBL] [Abstract][Full Text] [Related]
42. [Antiemetic efficacy of high-dose metoclopramide, diphenhydramine, methylprednisolone and diazepam on chemotherapy-induced emesis in gynecological malignancy].
Hayashi Y; Iwasaka T; Hachisuga T; Fukuda K; Tanaka T; Matsuo N; Sugimori H
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Jul; 40(7):875-9. PubMed ID: 3418195
[TBL] [Abstract][Full Text] [Related]
43. Metoclopramide kinetics at high-dose infusion rates for prevention of cisplatin-induced emesis.
Saller R; Hellenbrecht D; Briemann L; Hellstern A; Hess H; Mitrou P; Hodgson M; Achtert G; Brockmann P; Hausleiter HJ
Clin Pharmacol Ther; 1985 Jan; 37(1):43-7. PubMed ID: 4038385
[TBL] [Abstract][Full Text] [Related]
44. High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy.
Strum SB; McDermed JE; Liponi DF
J Clin Oncol; 1985 Feb; 3(2):245-51. PubMed ID: 4038511
[TBL] [Abstract][Full Text] [Related]
45. The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial.
Joss RA; Galeazzi RL; Bischoff AK; Pirovino M; Ryssel HJ; Brunner KW
Clin Pharmacol Ther; 1986 Jun; 39(6):619-24. PubMed ID: 3519041
[TBL] [Abstract][Full Text] [Related]
46. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
Manusirivithaya S; Chareoniam V; Isariyodom P; Sungsab D
J Med Assoc Thai; 2001 Jul; 84(7):966-72. PubMed ID: 11759977
[TBL] [Abstract][Full Text] [Related]
47. [A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine].
Nino S; Umehara H; Inoue I; Tamura T; Sasaki Y; Sakurai M; Shinkai T; Eguchi K; Saijo N; Suemasu K
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2881-4. PubMed ID: 3310905
[TBL] [Abstract][Full Text] [Related]
48. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
[TBL] [Abstract][Full Text] [Related]
49. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin.
Kris MG; Cubeddu LX; Gralla RJ; Cupissol D; Tyson LB; Venkatraman E; Homesley HD
Cancer; 1996 Nov; 78(10):2193-8. PubMed ID: 8918414
[TBL] [Abstract][Full Text] [Related]
50. A double-blind randomized cross-over comparison of high-dose prochlorperazine with high-dose metoclopramide for cisplatin-induced emesis.
Akhtar SS; Bano ZA; Bhat GM; Bhat MA
Oncology; 1991; 48(3):226-9. PubMed ID: 2023702
[TBL] [Abstract][Full Text] [Related]
51. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965
[TBL] [Abstract][Full Text] [Related]
52. Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.
Ballatori E; Roila F; Berto P; De Angelis V; Neri C; Olivieri A; Tonato M; Del Favero A
Pharmacoeconomics; 1994 Mar; 5(3):227-37. PubMed ID: 10146897
[TBL] [Abstract][Full Text] [Related]
53. Factors that influence the antiemetic activity of metoclopramide to cisplatin based chemotherapy.
Tsavaris N; Mylonakis N; Bacoyiannis C; Kosmas C; Kalergis G; Iakovidis V; Tzaninis D; Kosmidis P
Oncol Rep; 1998; 5(5):1147-55. PubMed ID: 9683826
[TBL] [Abstract][Full Text] [Related]
54. Progress in the control of acute and delayed emesis induced by cisplatin.
Gandara DR
Eur J Cancer; 1991; 27 Suppl 1():S9-11; discussion S22. PubMed ID: 1831633
[TBL] [Abstract][Full Text] [Related]
55. Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients.
Dogliotti L; Antonacci RA; Pazè E; Ortega C; Berruti A; Faggiuolo R
Drugs; 1992; 43 Suppl 3():6-10. PubMed ID: 1380432
[TBL] [Abstract][Full Text] [Related]
56. [Antiemetic combination of metoclopramide and methylprednisolone for cisplatin-induced vomiting].
Saito H; Amano H; Yasuda Y; Tsunekawa H; Fujimoto K; Yoshii S; Shimokata K
Gan To Kagaku Ryoho; 1985 Oct; 12(10):1980-2. PubMed ID: 4051514
[TBL] [Abstract][Full Text] [Related]
57. Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
Plosker GL; Milne RJ
Pharmacoeconomics; 1992 Oct; 2(4):285-304. PubMed ID: 10147044
[TBL] [Abstract][Full Text] [Related]
58. [Randomized controlled study of high-dose metoclopramide (2 mg/kg x 4:H) vs moderate-dose metoclopramide (1 mg/kg x 4:M) in the prevention of CDDP-induced emesis].
Dozono H; Ohmi K
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):454-7. PubMed ID: 3954370
[TBL] [Abstract][Full Text] [Related]
59. [A phase III trial comparing the antiemetic activity of tetracosactide with dexamethasone in combination with metoclopramide, diphenhydramine and clorazepate during chemotherapy including cisplatin].
Culine S; Azab M; Pietri F; Ghosn M; Ben Amor B; Lupera H; Theodore C; Renaux J; Droz JP
Bull Cancer; 1989; 76(6):583-9. PubMed ID: 2673437
[TBL] [Abstract][Full Text] [Related]
60. Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation.
Gilbert CJ; Ohly KV; Rosner G; Peters WP
Cancer; 1995 Dec; 76(11):2330-7. PubMed ID: 8635039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
